Tinaa
Members
-
Joined
-
Last visited
-
Community PostAs NICE NG89 includes day case and chemo as definition of an admission, I ideally want it covered for external reporting and data collection. We dont currently cohort
-
Community PostThank you everyone, we currently do not have a derogation policy in place for cohorts - does anyone have a policy for cohorts they could share with me please?
-
Community PostFor those of you who have the digital capability to collate VTE risk assessment compliance from all patients admitted aged 16 and over, do you include chemotherapy patients? I am having a lot of challenges with the inclusion of this patient cohort Nice is quite clear and states: Admission in the context of this guideline refers to admission as an inpatient, where a bed is provided for 1 or more nights, or admission as a day patient, where a bed is provided for a procedure including surgery or chemotherapy but not for an overnight stay.
-
Community PostFor those of you who have the digital capability to collate VTE risk assessment compliance from all patients admitted aged 16 and over, do you include chemotherapy patients? I am having a lot of challenges with the inclusion of this patient cohort Nice is quite clear and states: Admission in the context of this guideline refers to admission as an inpatient, where a bed is provided for 1 or more nights, or admission as a day patient, where a bed is provided for a procedure including surgery or chemotherapy but not for an overnight stay.
-
Community PostWe are updating out thromboprophylaxis policy at NGH: We still have a link to COVID-19 thromboprophylaxis, although we don’t routinely do this in practice. The NICE interim rapid guidance for thromboprophylaxis in COVID-19 is still referenced in the NICE thromboprophylaxis policy and so we can’t be seen to be deviating from national policy. Can I ask what the exemplar centres are doing about COVID-19 so we can decide if we should keep this in our policy?
